In the 2019 Annual Report, we present the results for patients diagnosed between 1st April 2017 and 31st March 2018 in England and Wales including:
1. The participation of NHS providers and the completeness and quality of the data submitted to the National Cancer Registration and Analysis Service (NCRAS), Public Health England and the Wales Cancer Network, Public Health Wales.
2. Patient demographic information, key aspects of the diagnostic and staging process they underwent and the treatments they received.
3. The variation in disease presentation and treatment allocation across NHS providers in England and Wales. For the first time, we report on the use of docetaxel, brachytherapy boost (high-dose rate and low-dose rate) and radiotherapy hypofractionation in England.
In addition, we present:
4. Treatment outcomes (up to two years post-treatment) for men in England and Wales undergoing radical prostatectomy (RP) or radical external beam radiotherapy (EBRT) in 2016.